The Catholic University of Korea Industry-Academic Cooperation Foundation

The Catholic Uiversity of Korea Industry-academic Cooperation Foundation

Tai Gyu Kim

Hyun Il Cho

Hyun Jung Sohn

Su Eon Kim

Su Yeon Kim

Hye Mi Park

Cheol Hwa Hong

Un Hee Kim

Hyun Woo Cho

The present invention relates to an exosome for stimulating T cells and the pharmaceutical use thereof. Immune exosomes secreted from artificial antigen-presenting cells which express HLA, CD32, and co-stimulatory molecules CD32, CD80, CD83, and 4-1BBL are used to stimulate naive CD8+ T cells whereby preventive and therapeutic effects on tumors, pathogen infections, or autoimmune diseases can be provided.

Exosome for stimulating T cell and pharmaceutical use thereof

The present invention relates to a novel feeder cell and a method for growing gamma delta T cells using the same. More specifically, a large amount of gamma delta T cells may be grown in vitro with high purity and without simulation of a T cell receptor by using a feeder cell into which costimulatory molecules are introduced and a low concentration of IL-2, differentiation into central memory cells may be possible when stimulated, activity by the feeder cell, and cytolytic against tumour cells is provided.

Feeder cell and method for growing gamma delta T cells by using same

The present invention relates to a HLA-A2 subtype-specific PLK1-derived epitope inducing an antigen-specific T cell immune response to a PLK1 protein. More specifically, a HLA-A2 subtype-specific PLK-1-derived epitope inducing an antigen-specific T cell immune response to a PLK1 protein according to the present invention can provide a CD8+ T cell immune response specific for tumor cells.

HLA-A2 subtype-specific PLK1-derived epitope inducing antigen-specific t cell immune response to PLK1 protein

The present invention relates to an artificial antigen-presenting cell prepared from an HLA-null cell line by using a multiplex CRISPR-Cas9 system and the use thereof and, more particularly, to a novel artificial antigen-presenting cell which includes the ability to present antigens of HLA class I and a co-stimulatory molecule group transferred from an HLA-A, -B, -C null cell line generated using a multiplex CRISPR-Cas9 system and to stimulate T cells, an immunotherapeutic agent using the same, and the use thereof for treating tumors, pathogenic infections, and autoimmune diseases.

Artificial antigen-presenting cell prepared from HLA-null cell line by using multiplex CRISPR-CAS9 system and use thereof

The present invention relates to an EBV antigen specific T-cell receptor and the use thereof. Specifically, the present invention provides T cells specific for LMP1 of EBV using a T-cell receptor which is highly specific for specific epitopes derived from an EBV antigen, LMP1. In addition, the EBV antigen specific T-cell can be used in the prevention or treatment of EBV-associated diseases.

EBV antigen specific T-cell receptor and use thereof

The present invention relates to a CD4 T cell vaccine and a use thereof, and provides a CD4 T cell vaccine which can increase intracellular viability and effectively induce an antigen-specific cytotoxic T lymphocyte (CTL) response.

CD4 T cell vaccine and use thereof

The present invention relates to tumor antigen proteins or genes derived from polo-like kinase 1. As a result of the formation of a complex by binding polo-like kinase 1-derived proteins or variants having characteristics functionally identical to the proteins with MHC class I antigens or II antigens, the complex can be recognized by cytotoxic T lymphocytes. Therefore, the polo-like kinase 1-derived proteins or variants are identified as a tumor antigen which can be generally used in tumor immunotherapy.

Growing community of inventors

Seoul, South Korea

Tai Gyu Kim